Form 4: Sangamo Therapeutics CEO Sandy Macrae Reports Stock Transactions for Tax Withholding
SEC Form 4 Filing
CEO Sandy Macrae surrendered shares of Sangamo Therapeutics stock to cover mandatory tax withholding obligations related to vesting restricted stock units (RSUs).
Summary
- On May 24 and May 25, 2024, Sandy Macrae, the CEO and a director of Sangamo Therapeutics, surrendered shares of common stock to the company for mandatory tax withholding purposes.
- These transactions were related to the vesting of restricted stock units (RSUs) granted under the company's Amended and Restated 2018 Equity Incentive Plan.
- On May 24, 5,261 shares were surrendered at a price of $0.60 per share.
- On May 25, 7,492 shares were surrendered at a price of $0.60 per share.
- Following these transactions, Macrae beneficially owns 2,539,451 shares of Sangamo Therapeutics common stock.
- These shares include unvested portions of RSU grants from February 2022, February 2023, and January 2024, which vest over time subject to continued service.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting required transactions. The fact that the CEO is vesting RSUs is mildly positive, suggesting continued service and alignment with company goals. However, the stock price of $0.60 is relatively low, which tempers the overall sentiment.
Positives
- The transactions are related to the vesting of previously granted RSUs, indicating that the CEO is meeting the conditions for those grants.
- The CEO still holds a significant number of shares (2,539,451), aligning his interests with those of the shareholders.
Future Outlook
The CEO's remaining RSU grants will continue to vest over time, subject to continued service, as per the vesting schedules outlined in the document.
Industry Context
Form 4 filings are standard practice for company insiders and provide transparency into their transactions in the company's stock. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider transactions.
- The vesting schedules and equity incentive plans are common practices in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.
- Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize RSU grants as part of their compensation packages for executives.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, as they are related to tax withholding and do not represent a change in the CEO's overall commitment to the company.
- Employees holding RSUs may be interested in the vesting schedules and tax implications of their grants.
Key Dates
| Date | Description |
|---|---|
| 02/25/2022 | Date of RSU grant that will vest in successive equal quarterly installments through February 25, 2025 |
| 02/24/2023 | Date of RSU grant that will vest in successive equal quarterly installments through February 24, 2026 |
| 01/22/2024 | Date of RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. |
| 05/24/2024 | Date of transaction where 5,261 shares were surrendered for tax withholding at $0.60/share. |
| 05/25/2024 | Date of transaction where 7,492 shares were surrendered for tax withholding at $0.60/share. |
| 05/29/2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.